CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 52 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04520165
NCT04520165N/AActive

Effect of Anti-IL5 and Anti-IgE on Alternative Functions of Eosinophils in Severe Asthma

University of Liege·observational·Posted Aug 20, 2020·Updated Oct 4, 2024

In Brief

An observational study for Severe Asthma. Active but no longer recruiting, targeting 52 participants across 1 site.

Detailed Summary

The investigators will measure different cytokines in the sputum (interleukin ((IL))-3, granulocyte-macrophage colony-stimulating factor ((GM-CSF)), IL5, IL-13, IL-33, IL-4, IL-25 thymic stromal lymphopoietin ((TSLP)) and eotaxin-1 ) and in the blood to evaluate their ability to predict the response after 6 months and 1 year of treatment with a biologic treatment (anti-IgE, anti-IL5, anti-IL5R) in terms of reduction in exacerbations and corticosteroid use, improvement in Forced expiratory volume in the first second (FEV1) (+200ml), in asthma control (ACQ decrease \>0.5, ACT increase \>3), in asthma quality of life (increase in AQLQ score \> 0.5) and the effect on sputum and blood inflammation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Asthma
CountriesBelgium
Collaborators--

Timeline

N/AActiveOverdue
2014201520162017201820192020202120222023202420252026
First PostedAug 20, 2020
Enrollment StartJan 1, 2014
Primary CompletionJan 26, 2023
Study CompletionAug 31, 2025
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 5.9 years ago